Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

• Status: Unknown status
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of our study is to improve the major molecular remission(MMR) rate and reduce the cost to treat ph(+) Acute Lymphoblastic Leukemia (ALL) by adjusting chemotherapy regimens and the dosage of Tyrosine Kinase Inhibitor (TKI). lower the classification of chemotherapy drugs, lower the side effect brought by which this would be a grateful news for the patients once this regimens gain a successful result, which is also the final aim of our efforts.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tongji Hospital
• Treatments: BB 1101; Dasatinib; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Methotrexate; Prednisone

Criteria

Inclusion Criteria:

1. Get signed the informed consent of patients and family members

2. Age ≥ 18 one full year of life

3. Confirm the ph + ALL at molecular biology level

4. Normal heart and lungs function

5. Normal liver and kidney function

Exclusion Criteria:

1. Leukemia in the nervous system

2. Recurrent patients

3. Allergies associated with any drug in our research

4. At the same time with other organs' malignant tumours

5. participating in other clinical researches at the same time